Open AccessSafety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
Author(s) -
Jeffrey S. Weber,
Ragini R. Kudchadkar,
Bin Yu,
Donna Gallenstein,
Christine E. Horak,
H. David Inzunza,
Xiuhua Zhao,
Alberto J. Martinez,
Wenshi Wang,
Geoffrey T. Gibney,
Jodi L. Kroeger,
Cabell Eysmans,
Amod A. Sarnaik,
Y. Ann Chen
Publication year - 2013
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2013.51.4802
Subject(s) - ipilimumab , nivolumab , medicine , refractory (planetary science) , melanoma , oncology , response evaluation criteria in solid tumors , adverse effect , immunotherapy , gastroenterology , immunology , phases of clinical research , clinical trial , cancer , cancer research , physics , astrobiology
Nivolumab, a human immunoglobulin G4-blocking antibody against the T-cell programmed death-1 checkpoint protein, has activity against metastatic melanoma. Its safety, clinical efficacy, and correlative biomarkers were assessed with or without a peptide vaccine in ipilimumab-refractory and -naive melanoma.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom